Le Lézard
Classified in: Health

Dr. Vasken Dilsizian Will Present Keynote Lecture at ASNC2024


FAIRFAX, Va., March 25, 2024 /PRNewswire-PRWeb/ -- Renowned cardiovascular researcher, physician and educator Vasken Dilsizian, MD, MASNC, will present the Mario Verani Memorial Lecture at the American Society of Nuclear Cardiology (ASNC) 2024 Annual Scientific Session and Exhibition. Dr. Dilsizian's ASNC2024 lecture, titled "50 Years of Myocardial Perfusion Imaging," will trace nuclear cardiology's history, highlighting key moments in the field's vibrant past that suggest exciting opportunities for current and future advancements.

At ASNC2024, we will examine how our journey through several perfusion agents, technological advances and now absolute blood flow measurement has made nuclear cardiology unique among imaging modalities for detecting coronary artery disease. ? Dr. Vasken Dilsizian, Mario Verani Memorial Lecturer

Selection as a Mario Verani Memorial Lecturer is one of the highest honors bestowed by ASNC. The award recognizes qualities exemplified by the late Dr. Mario S. Verani, a founding member of ASNC and a leader who inspired a generation of nuclear cardiologists. Dr. Verani is remembered at every ASNC annual meeting for his seminal contributions to nuclear cardiology, excellence as a teacher and a clinician, and for being a caring physician.

Dr. Dilsizian's professional journey began in the 1970s, when Dr. Verani and other visionary clinician-scientists were establishing the field of nuclear cardiology. As a young physician and then a graduate student in chemical engineering, Dr. Dilsizian took a series of "chances" that, time and again, led him to places where he used his background in internal medicine, cardiology and nuclear medicine to move nuclear cardiology forward. He was the director of nuclear cardiology at the National Institutes of Health (NIH) from 1992 to 2001 and then joined the University of Maryland School of Medicine as a professor of radiology and medicine. He became chief of the division of nuclear medicine at the University of Maryland Medical Center in 2007.

"Nuclear cardiology's growth coincides with my career, from college, graduate school, 13 years at the NIH investigating myocardial perfusion imaging and myocardial viability, to my current work in hybrid PET/CT and molecular imaging," Dr. Dilsizian says. "At ASNC2024, we will examine how our journey through several perfusion agents, technological advances and now absolute blood flow measurement has made nuclear cardiology unique among imaging modalities for detecting coronary artery disease."

Dr. Dilsizian's research efforts over the past 35 years have resulted in more than 280 journal publications, 11 books and 51 book chapters. He is the deputy editor of JACC: Cardiovascular Imaging and a section editor for both the Journal of the American College of Cardiology and Current Cardiology Reports. He has been a co-author or co-editor of four key cardiology textbooks: Atlas of Nuclear Cardiology (now in its 5th edition), Cardiac CT, PET and MR (now in its 3rd edition), Atlas of Cardiac Innervation and the "Nuclear Cardiology" chapter of Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine.

A past president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and a past vice president of ASNC, Dr. Dilsizian has received numerous awards for his many contributions to the science of nuclear cardiology. He has also served as the chair of the American College of Cardiology Task Force on Clinical Competence and Training in Nuclear Cardiology (COCATS), vice chair of the NIH Clinical Center's Board of Scientific Counselors and vice chair of the Nuclear Regulatory Commission's Advisory Committee on the Medical Use of Isotopes.

About ASNC2024
The ASNC2024 Main Program will convene Sept. 5-7 at the JW Marriott Austin in Austin, Texas, USA. Dr. Dilsizian will present the Mario Verani Memorial Lecture during the Opening Plenary Session on Thursday, Sept. 5, at 8:30 AM (U.S. Central Time). Attendees may choose in-person or virtual registration.

ABOUT THE AMERICAN SOCIETY OF NUCLEAR CARDIOLOGY 
The American Society of Nuclear Cardiology and its more than 5,200 members have been improving cardiovascular outcomes through image-guided patient management for more than 30 years. As the leading society dedicated solely to the field of nuclear cardiology, ASNC establishes standards for excellence in cardiovascular imaging through the development of clinical guidelines, professional medical education, advocacy and research. ASNC provides peer-reviewed original articles through its official publication, The Journal of Nuclear Cardiology. For more information, visit http://www.asnc.org.

Media Contact

Kathy Boyd David, American Society of Nuclear Cardiology, 717-422-1181, [email protected], www.asnc.org

Twitter

SOURCE American Society of Nuclear Cardiology


These press releases may also interest you

at 20:15
AriBio Co., Ltd. (AriBio) announced authorisation from the European Medicines Agency (EMA) for POLARIS-AD (AR1001-ADP3-US01), a global, phase 3, early Alzheimer's disease clinical trial. EMA now aligns with the U.S. Food and Drug Administration (FDA)...

at 19:34
Celltrion USA announced today that it has signed an agreement with Express Scripts, one of the nation's leading pharmacy benefit managers (PBMs) negotiating on behalf of health plans covering more than 100 million people. The agreement, effective...

at 16:48
Marc Dubrick and Lisa Becharas are bringing victories home to Boulder, Colorado, after winning their first St. Anthony's Triathlon along St. Petersburg's scenic downtown waterfront. The winners, who are teammates on The Real Triathlon Squad, raced a...

at 16:30
Nicholas Baker, M.D., Director of Robotic Thoracic Surgery at the University of Pittsburgh Medical Center (UPMC) Passavant, presented key findings from independent research at the 104th Annual Meeting of the American Association for Thoracic Surgery...

at 15:40
Sexton Lawn & Landscapes is thrilled to announce the appointment of Brooks Breland as the leading Lawn and Plant Health Expert. In this role, Breland will...

at 12:00
OBiO Technology (Shanghai) Corp., Ltd. (OBiO, 688238.SH), a world leading contract development and manufacturing organization for cell and gene therapy, will showcase at American Society of Gene & Cell Therapy in Maryland, USA from May 7th to 11th. 9...



News published on and distributed by: